Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Sylvie Fisher

Physician Assistant Enid, OK Physician Assistant

NPI 1578038857 CMS profile 11222061

825 E Owen K Garriott Rd, Enid, OK 73701

Open in the dashboard

General payments

$477

20 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sylvie Fisher of Enid, OK is reported in the CMS Open Payments database as having received $477 across 20 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 55th percentile of Physician Assistant profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $298 15
2024 General $33 2
2023 General $146 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sylvie Fisher
  • Physician Assistant median
  • Middle half of Physician Assistant
  • National median

In program year 2025, general payments to Sylvie Fisher were reported at $298. Among 68,903 Physician Assistant profiles paid that year, the median was $184 and the middle half received between $57 and $620.

Show as a table
Year Sylvie Fisher Physician Assistant median Middle half National median
2019 $0 $34 $17–$122 $163
2020 $0 $33 $16–$78 $114
2021 $0 $132 $37–$438 $132
2022 $0 $155 $48–$522 $149
2023 $146 $167 $52–$557 $160
2024 $33 $178 $55–$600 $164
2025 $298 $184 $57–$620 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. AstraZeneca Pharmaceuticals LP $186 7 payments
  2. Novartis Pharmaceuticals Corporation $67 3 payments
  3. Alexion Pharmaceuticals, Inc. $61 1 payment
  4. Amgen Inc. $51 3 payments
  5. AbbVie, Inc. $41 2 payments
  6. Horizon Therapeutics plc $24 1 payment
  7. Genentech USA, Inc. $18 1 payment
  8. GlaxoSmithKline, LLC. $16 1 payment
  9. UCB, Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $477 20 payments
Products named General payments · program years 2023–2025
  1. SAPHNELO $186 7 payments
  2. COSENTYX $67 3 payments
  3. ULTOMIRIS $61 1 payment
  4. RINVOQ $41 2 payments
  5. KRYSTEXXA $24 1 payment
  6. UPLIZNA $20 1 payment
  7. GAZYVA $18 1 payment
  8. Otezla $17 1 payment
  9. BENLYSTA $16 1 payment
  10. Bimzelx $14 1 payment
  11. Other $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 32 drugs

Part D claims

2,021

Median for Physician Assistant: 241

Drug cost

$897,083

Median for Physician Assistant: $4,110

Branded share of claims

27.4%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Simponi Aria Golimumab Brand 42 $340,479
Humira(Cf) Pen Adalimumab Brand 31 $256,385
Xeljanz Xr Tofacitinib Citrate Brand 19 $106,585
Benlysta Belimumab Brand 26 $92,896
Gammagard Liquid Immun Glob G(Igg)/Gly/Iga Ov50 Brand 18 $68,161
Hydroxychloroquine Sulfate Generic 347 $10,852
Celecoxib Generic 254 $4,870
Sulfasalazine Dr Sulfasalazine Brand 155 $2,382
Methotrexate Methotrexate Sodium Brand 194 $2,131
Leflunomide Generic 63 $2,051

The 10 drugs with the highest cost, of 32 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 89 billing codes

Paid by Medicare

$1,183,478

Of which drugs: $1,044,923

Medicare patients

380

Average age 71

Services billed

95,098

321 women, 59 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 29%
Depression 29%
Ischemic heart disease 28%
Osteoporosis 26%
Chronic kidney disease 24%
COPD 22%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, golimumab, 1 mg, for intravenous use J1602 Office 92 30,815 $276,691
Injection, infliximab, excludes biosimilar, 10 mg J1745 Office 55 8,000 $198,629
Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) J0129 Office 19 3,850 $129,428
Injection, tocilizumab, 1 mg J3262 Office 27 27,423 $126,212
Injection, belimumab, 10 mg J0490 Office 12 2,593 $100,662
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg J1569 Office 13 1,840 $65,860
Injection, denosumab, 1 mg J0897 Office 22 1,440 $29,563
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 83 1,273 $945
Injection, ketorolac tromethamine, per 15 mg J1885 Office 109 573 $286
Injection, methylprednisolone sodium succinate, up to 125 mg J2930 Office 50 58 $254

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SAPHNELO
  • AstraZeneca Pharmaceuticals LP $33
$33 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

20 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant in Oklahoma

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record